Daniel is an experienced Oncology biologist who brings a wealth of early drug discovery experience both in the USA and Europe to Ridgeline Discovery.

Prior to joining Ridgeline, Daniel worked at Roche as a Group Leader in the Oncology DTA. At Roche he was a program leader for multiple early drug discovery programs that focused on identifying novel targets and moving them into the clinic. Prior to Roche he held an Oncology early discovery position at GlaxoSmithKline in the USA.

Daniel obtained his PhD from Weill Cornell Graduate School of Medical Sciences while working at Memorial Sloan Kettering in a collaboration with Agios Pharmaceuticals.